Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.55 |
| ▸ | IGF1R | P08069 | 1/20 | 0.53 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.52 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.52 |
| ▸ | PTK2 | Q05397 | 9/20 | 0.51 |
| ▸ | AURKA | O14965 | 1/20 | 0.51 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.51 |
| ▸ | HTR7 | P34969 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.49 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16972143 | 0.85 | PTPN7 (0.56) | LRRK2ROCK2ROCK1AURKAAURKB | |
| SCHEMBL22280207 | 0.85 | KMT2A (0.52) | PTK2HTR7ALDH1A1NPSR1KMT2A | |
| SCHEMBL24136244 | 0.84 | MAOB (0.50) | LRRK2HTR7ALDH1A1KMT2A | |
| SCHEMBL9964598 | 0.84 | BRD4 (0.55) | LRRK2IGF1RROCK2ROCK1AURKA | |
| SCHEMBL410671 | 0.83 | AURKA (0.52) | LRRK2IGF1RROCK2ROCK1PTK2 | |
| SCHEMBL15082471 | 0.83 | AURKA (0.57) | LRRK2IGF1RROCK2ROCK1PTK2 | |
| SCHEMBL738237 | 0.83 | HTR4 (0.53) | LRRK2ROCK2ROCK1PTK2AURKA | |
| SCHEMBL21473640 | 0.81 | PTK2 (0.56) | LRRK2IGF1RROCK2ROCK1PTK2 | |
| SCHEMBL13880647 | 0.80 | AURKA (0.52) | LRRK2ROCK2ROCK1PTK2AURKA | |
| SCHEMBL22182518 | 0.79 | PTK2 (0.52) | IGF1RPTK2KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11208412-B2 | Pyrrolo-pyrimidine derivative compound, preparation method therefor, and pharmaceutical composition comprising same compound as effective ingredient for preventing or treating protein kinase-related disease | DAEGU-GYEONGBUK MEDICAL INNOVATION FOUNDATION (KR) | 2021-12-28 | — | — | US | disclosed |
| US-20200239474-A1 | PYRROLO-PYRIMIDINE DERIVATIVE COMPOUND, PREPARATION METHOD THEREFOR, AND PHARMACEUTICAL COMPOSITION COMPRISING SAME COMPOUND AS EFFECTIVE INGREDIENT FOR PREVENTING OR TREATING PROTEIN KINASE-RELATED DISEASE | DAEGU-GYEONGBUK MEDICAL INNOVATION FOUNDATION (KR) | 2020-07-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11208412-B2 | Pyrrolo-pyrimidine derivative compound, preparation method therefor, and pharmaceutical composition comprising same compound as effective ingredient for preventing or treating protein kinase-related disease | LRRK2, WEE1, WEE2 | LRRK2 1/4885IGF1R 1336/4885ROCK2 1138/4885 |
| US-20200239474-A1 | PYRROLO-PYRIMIDINE DERIVATIVE COMPOUND, PREPARATION METHOD THEREFOR, AND PHARMACEUTICAL COMPOSITION COMPRISING SAME COMPOUND AS EFFECTIVE INGREDIENT FOR PREVENTING OR TREATING PROTEIN KINASE-RELATED DISEASE | LRRK2, WEE1, WEE2 | LRRK2 1/4885IGF1R 1336/4885ROCK2 1138/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.